Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia (NCT02677064)

🧪 Interventions in This Study

• assessments (OTHER)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients with newly diagnosed or relapsed acute leukemia. Patients undergoing reinduction due to primary induction failure are also eligible. Patients with acute leukemia will be enrolled to Arm A
2. Patients with diagnosis of MDS, MPN and MDS/MPN overlap who meet any of the following criteria (based on NCCN guidelines):
3. Clinically significant cytopenia of at least 2 cell lines affected; Hgb\<10,
4. Platelet\<100,000, absolute neutrophil count\<1000
5. Bone marrow blasts \>5% and any level of circulating blasts
6. Evidence of disease progression or no response to hypomethylating agents/immunosuppressive treatment or a clinical trial.
7. IPSS Intermediate-1 and higher
8. IPSS-R intermediate and higher
9. All cases of therapy related MDS with excess blasts
10. In patients with Myelofibrosis: Low risk disease by DIPSS with either refractory, transfusion dependent anemia, circulating blasts cells greater than 2%; or adverse cytogenetics and any patient with DIPSS-intermediate 1 and higher. For patients with post-PV and post-ET myelofibrosis, any patient with MYSEC-PM Intermediate-1 risk or higher is eligible.
11. Patients with acute leukemia or MDS/MPN who relapse after first allografts. Patients with post-transplant relapse will be enrolled to Arm C.
12. Patients 18 years of age or older and 80 years of age or younger

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (3 Sites)

• Hartford Healthcare Cancer Institute @ Hartford Hospital — Hartford, Connecticut
• Memorial Sloan Kettering Cancer Center — New York, New York
• Lehigh Valley Health Network — Allentown, Pennsylvania

📞 Contact the Study Coordinator

Phone: (860) 249-6291

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Leukemia

• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — Valhalla, New York
• Cytogenetic Studies in Acute Leukemia and Multiple Myeloma — La Jolla, California
• Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing — Boston, Massachusetts
• Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant — Duarte, California
• ATG Plus PTCy vs ATG for CGVHD Prophylaxis — Darlinghurst, New South Wales

Explore by condition: All Acute Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.